Per-attack reporting of prodromal symptoms concurrent with c1-inhibitor treatment of hereditary angioedema attacks.
Adv Ther., Oct;29(10):913-22 (2012)
C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life.
Allergy Asthma Proc., 33(5):427-31 (2012 Sep-Oct)
Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Allergy Asthma Proc., 33(4):354-61 (2012 Jul-Aug)
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
J. Allergy Clin. Immunol., Oct;130(4):951-7.e11 (2012)
Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again.
J. Clin. Immunol., Jul (2012)
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.
J. Clin. Immunol., Aug;32(4):663-9 (2012)
Safety of L-proline as a stabilizer for immunoglobulin products.
Expert Rev Clin Immunol., Feb;8(2):169-78 (2012)
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
Clin Pharmacokinet., Jun;50(6):405-14 (2011)
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.
J. Clin. Immunol., Jun;31(3):323-31 (2011)
Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity.
Allergy Asthma Proc., 32(1):36-42 (2011 Jan-Feb)
Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks.
Ann. Allergy Asthma Immunol., Jan;106(1):62-8 (2011)
Office-based oral immunotherapy for food allergy is safe and effective.
J. Allergy Clin. Immunol., Jan;127(1):290-1; author reply 291-2 (2011)
Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease.
Emerging Infect. Dis., Sep;16(9):1341-8 (2010)
Diagnosis and treatment of primary immunodeficiency disease: the role of the otolaryngologist.
Am J Otolaryngol., 32(4):329-37 (2011 Jul-Aug)
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks.
Ann. Allergy Asthma Immunol., Aug;105(2):149-54 (2010)
Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema.
J. Clin. Immunol., Nov;30(6):823-9 (2010)
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
J. Clin. Immunol., Sep;30(5):734-45 (2010)
Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology.
Clin. Immunol., May;135(2):255-63 (2010)
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.
J. Allergy Clin. Immunol., Oct;124(4):801-8 (2009)
Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
Eur J Pharm Sci., Jun;37(3-4):272-8 (2009)